91 related articles for article (PubMed ID: 121949)
1. Osmotic blood-brain barrier disruption: a new means of increasing chemotherapeutic agent delivery.
Neuwelt EA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Hill SA; Lewis SE; Ehle AL; Beyer CW; Moore RJ
Trans Am Neurol Assoc; 1979; 104():256-60. PubMed ID: 121949
[No Abstract] [Full Text] [Related]
2. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
[TBL] [Abstract][Full Text] [Related]
3. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats.
Cosolo W; Christophidis N
Cancer Res; 1987 Dec; 47(23):6225-8. PubMed ID: 3119195
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
5. [Hemodynamic effects of an osmotic bolus for the reversible opening of the blood-brain barrier].
Hiesmayr M; Dirnberger H; Aloy A; Heimberger K; Horaczek A; Brandstätter B; Zimpfer M
Schweiz Med Wochenschr; 1987 Mar; 117(12):450-4. PubMed ID: 3107120
[TBL] [Abstract][Full Text] [Related]
6. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors.
Neuwelt EA; Rapoport SI
Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941
[TBL] [Abstract][Full Text] [Related]
7. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
[TBL] [Abstract][Full Text] [Related]
8. Re: Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
Goldstein DA; Tessler HH
Am J Ophthalmol; 2007 Dec; 144(6):976; author reply 976. PubMed ID: 18036877
[No Abstract] [Full Text] [Related]
9. Intracarotid infusion of hypertonic mannitol changes permeability of blood-brain barrier to methotrexate in rats.
Pan GY; Liu XD; Liu GQ
Acta Pharmacol Sin; 2000 Jul; 21(7):613-6. PubMed ID: 11360668
[TBL] [Abstract][Full Text] [Related]
10. Technique of, and complications attributable to, repeated hyperosmotic blood-brain barrier disruption in dogs.
Culver B; Inzana K; Jones J; Troy G; Kroll R; Culver B; Jortner B
Am J Vet Res; 1998 Nov; 59(11):1503-10. PubMed ID: 9829415
[TBL] [Abstract][Full Text] [Related]
11. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
Miyagami M; Kagawa Y; Tsubokawa T
No Shinkei Geka; 1985 Sep; 13(9):955-63. PubMed ID: 2999632
[TBL] [Abstract][Full Text] [Related]
12. Use of enhanced computerized tomography to evaluate osmotic blood-brain barrier disruption.
Neuwelt EA; Maravilla KR; Frenkel EP; Barnett P; Hill S; Moore RJ
Neurosurgery; 1980 Jan; 6(1):49-56. PubMed ID: 6153461
[TBL] [Abstract][Full Text] [Related]
13. The blood-brain barrier disruption controversy: does it hold water?
Ruffer JE; Glatstein E
Cancer J Sci Am; 1998; 4(2):84-5. PubMed ID: 9532409
[No Abstract] [Full Text] [Related]
14. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
Yamada K; Takahama H; Nakai O; Takanashi T; Hosoya T
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2692-6. PubMed ID: 2506817
[TBL] [Abstract][Full Text] [Related]
15. Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier.
Neuwelt EA; Frenkel EP; D'Agostino AN; Carney DN; Minna JD; Barnett PA; McCormick CI
Cancer Res; 1985 Jun; 45(6):2827-33. PubMed ID: 2985254
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption.
Neuwelt EA; Diehl JT; Vu LH; Hill SA; Michael AJ; Frenkel EP
Ann Intern Med; 1981 Apr; 94(4 pt 1):449-54. PubMed ID: 6782926
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening.
Neuwelt EA; Balaban E; Diehl J; Hill S; Frenkel E
Neurosurgery; 1983 Jun; 12(6):662-71. PubMed ID: 6410302
[TBL] [Abstract][Full Text] [Related]
18. CT monitoring of chemotherapeutic agent delivery after osmotic blood brain barrier disruption.
Neuwelt EA
Clin Neurosurg; 1981; 28():520-31. PubMed ID: 6895614
[No Abstract] [Full Text] [Related]
19. Intra-arterial chemotherapy following blood-brain barrier disruption in a patient with malignant glioma.
Hill SA; Neuwelt EA
J Neurosurg Nurs; 1982 Apr; 14(2):94-7. PubMed ID: 6811704
[No Abstract] [Full Text] [Related]
20. [Blood-brain barrier opening microcirculation in human brain tumor].
Sato S; Toya S; Otani M
No To Shinkei; 1985 Feb; 37(2):109-13. PubMed ID: 2988587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
